What Is Epithalon?

Epithalon (Ala-Glu-Asp-Gly) is a four-amino-acid peptide developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. It is a synthetic version of Epithalamin, a polypeptide extract from the bovine pineal gland.

Khavinson's research on Epithalon spans over 35 years and includes animal studies, cell culture experiments, and human clinical observations. His work earned recognition from the Russian Academy of Medical Sciences, and Epithalamin was used clinically in Russia for several decades.

The key innovation of Epithalon is that it provides the bioactive component of Epithalamin in a pure, reproducible synthetic form — eliminating the need for animal-derived extracts.

Epithalon's primary mechanism centers on telomerase activation:

• Telomerase activation: Epithalon stimulates the expression of hTERT (human telomerase reverse transcriptase), the catalytic component of telomerase. This enzyme adds TTAGGG repeats to telomere ends, counteracting age-related shortening.
• Pineal gland modulation: Epithalon may restore pineal gland function and normalize melatonin production, which declines with age
• Circadian rhythm regulation: Through melatonin normalization, Epithalon can help regulate disrupted sleep-wake cycles
• Antioxidant gene expression: Research shows Epithalon upregulates antioxidant enzymes and reduces lipid peroxidation
• Neuroendocrine regulation: The peptide appears to have broad effects on hypothalamic-pituitary function, potentially normalizing age-related hormonal decline

The telomerase activation effect is the most significant — it directly addresses one of the fundamental mechanisms of cellular aging.

Research spanning decades has documented several potential benefits:

• Telomere elongation: Cell culture and animal studies demonstrate measurable increases in telomere length with Epithalon treatment
• Lifespan extension: Multiple animal studies show 10–25% lifespan increases in treated vs. control groups
• Melatonin restoration: Older subjects showed normalized melatonin production patterns after Epithalon administration
• Improved sleep: Through melatonin normalization, users report significantly improved sleep quality
• Cancer resistance: Paradoxically, despite activating telomerase, animal studies show reduced spontaneous tumor incidence — possibly through improved immune surveillance
• Retinal health: Studies in retinitis pigmentosa models show preservation of retinal structure and function
• Antioxidant status: Reduced markers of oxidative stress in treated subjects

Epithalon is administered via subcutaneous or intramuscular injection. Standard research protocols include:

• Dose: 5–10 mg per day
• Duration: 10–20 days per cycle
• Frequency: 2–3 cycles per year, spaced 4–6 months apart
• Administration: Subcutaneous injection, typically in the abdominal area

The cyclical dosing pattern reflects Khavinson's original protocols and the peptide's proposed mechanism — periodic stimulation of telomerase rather than continuous exposure.

Reconstitution: Reconstitute lyophilized powder with bacteriostatic water. Refrigerate after reconstitution.

Dosages are based on Khavinson's published research protocols. Work with a healthcare provider for individualized guidance.

Epithalon has demonstrated an excellent safety profile across decades of research:

• Minimal reported side effects: Most studies report no significant adverse effects at standard doses
• Injection site reactions: Minor, transient redness or soreness at the injection site
• Cancer concern: The theoretical concern that telomerase activation could promote cancer has not been supported by the evidence — animal studies actually show reduced tumor incidence
• Sleep changes: Increased melatonin production may cause drowsiness, which is typically considered a benefit

Khavinson's research group has documented safety across animal and human studies spanning over 15 years. However, most published research comes from Russian institutions, and large-scale Western clinical trials have not been conducted.

Epithalon requires careful synthesis and handling. We recommend Ascension Peptides for sourcing:

• 99%+ purity confirmed through HPLC analysis
• Proper tetrapeptide sequencing verified via mass spectrometry
• Batch-specific COAs available for every lot
• Temperature-controlled shipping to maintain peptide integrity

As a DailyVial affiliate partner, Ascension Peptides provides the quality verification essential for meaningful longevity research.